At Day One, we’re committed to making a difference not just in our work, but in the communities where we, our patients, and their families live and thrive. During our first annual Day One Gives Back Day, our team came together to volunteer and support causes and organizations in their local communities. Family House Inc., There With Care, and Ronald McDonald House of Central & Northern New Jersey. #CommittedFromDayOne #DayOneGivesBack
Day One Biopharmaceuticals
Biotechnology Research
Brisbane, California 15,621 followers
Cancer drug development comes of age.
About us
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
- Website
-
http://www.dayonebio.com
External link for Day One Biopharmaceuticals
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Brisbane, California
- Type
- Public Company
- Founded
- 2018
- Specialties
- Oncology, Cancer, Drug Development, Biotechnology, Pediatric Oncology, Targeted Therapies, MAPK, Neuro-Oncology, Glioma, Childhood Cancer, Translational Medicine, Hematology, and Glioma
Locations
-
Primary
2000 Sierra Point Pkwy
Brisbane, California 94005, US
Employees at Day One Biopharmaceuticals
Updates
-
Excited to share that Elly Barry, MD, Chief Medical Officer at Day One, will be featured on the upcoming MIB Agents Osteosarcoma Alliance OsteoBites webinar! As a co-leader of the ACCELERATE Fit for Filing Working Group, Dr. Barry will provide insights into the principles guiding data packages for regulatory filings, roles and responsibilities in collaborative studies, and the resources needed to operationalize and deliver these critical trials. Join on August 29th to gain an industry perspective on how academic-sponsored trials can directly contribute to the licensing of new medicines. Learn more: https://bit.ly/4fW828d
-
-
Thank you to ALADDIN Education and Sara Wakeling (Craddock) for featuring our CDO, Davy Chiodin, alongside Delphine Heenen, Managing Director of KickCancer, on the latest ALADDIN Podcast episode! They discussed innovative strategies like repurposing shelved drugs to discover new possibilities in pediatric drug development. Listen here: https://lnkd.in/g_Uz3Fn6
🛎 Our NEW episode is here 🛎 In the latest hashtag #ALADDIN episode, Sara Wakeling (Craddock) speaks to the Chief Development Officer of Day One Biopharmaceuticals Dr Davy Chiodin and the Managing Director of KickCancer, Delphine Heenen about drug repurposing and shelved drug rescuing. Listen now on: 👉 Spotify: https://ow.ly/glVT50SWyRf 👉 Apple: https://ow.ly/rZYa50SWyTa
-
We’re excited to share that we’re expanding our #clinicalpharmacology team, and we’re looking for a passionate individual to serve as a strategic leader of Day One’s anti-body-drug conjugate (ADC) program. Ready to join us in driving change in oncology for patients of all ages? Apply today! Check out our Director, Clinical Pharmacology role: https://bit.ly/4cyFcrR #WereHiring #JoinOurTeam
-
-
Day One reports second quarter 2024 financial results. Read more here: https://bit.ly/4fqvutX
-
-
We are pleased to announce a new ex-U.S. licensing agreement with Ipsen to commercialize tovorafenib. This collaboration highlights our shared commitment to bring novel therapeutics to patients worldwide who have limited treatment options. Learn more: https://bit.ly/4fjDBIP
-
-
#WereHiring: Are you a Medical Affairs Leader open to exploring your next opportunity that will directly impact the field of adult and pediatric oncology drug development? We are seeking a dynamic leader to drive medical affairs strategy and who has an outstanding track record of building and leading high-performance organizations and partnerships as VP, Head of Medical Affairs. Apply here: https://bit.ly/3LxC3NU Or reach out to our Talent Acquisition team, Lindsey Summers 🎗💛, Jenny Lash, Ryan Sanders, to learn more. #Hiring #JoinOurTeam
-
-
Thank you to Simone Fishburn, BioCentury's Editor in Chief, for having our CEO, Jeremy Bender, on The #BioCenturyShow's recent episode to talk about Day One Biopharmaceuticals' approach to drug development and its strategy for long-term sustainability. Listen to the full episode here: https://bit.ly/3RYf560
On The #BioCenturyShow, Day One Biopharmaceuticals CEO Jeremy Bender joined BioCentury's Editor in Chief Simone Fishburn to talk: ➤ Pediatric cancer drug development, with opportunities for adult applications ➤ First v. best in class ➤ Advancements with ADCs ➤ How to turn a start-up into a commercial entity at lightening speed Watch the full interview now on YouTube or listen to "The BioCentury Show" on your favorite podcast platform: https://lnkd.in/gKkZuRqN Learn more: https://lnkd.in/gguT9TcA #drugdevelopment #pediatriccancer #ADCs
-
Day One welcomes the Pediatric Neuro-Oncology community to ISPNO! Connect with peers at our reception and hear from Day One leaders on the collaboration between academia and industry in advancing pediatric drug development. Learn more and register here: https://bit.ly/3xxJ6CC
-